TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors

Tumor organoids and TILs (and/or peripheral T cells) cultures will be established from fresh tissure of lung cancer and other solid tumors. Coculture will be utilized to screen tumor-responsive T cells which are further selected for monoclonal expansion and TCR cloning for engineered reconstitution of TCR-T cells. After verification by multiple in vitro and in vivo studies, a large number of TCR-T cells will be introduced back into the patients via vein, artery or fine needle punctured to the tumor, or combinations. In this phase I study, the safety, tolerance and preliminary efficacy of the T

Trial Details

NCT ID
NCT03778814
Phase
PHASE1
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • TCR-T cells
Locations (sample)
  • Guanzhou, Guangdong, China|23.06828,113.37117

Key Eligibility Criteria

  • patients with advanced lung tumor or other solid tumor where biopsy is obtainable
  • Life expectancy \>12 weeks
  • Child-Pugh-Turcotte score \<7
  • Adequate heart,lung,liver,kidney function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →